| Previous close | 8.50 |
| Open | 8.50 |
| Bid | 6.00 |
| Ask | 11.00 |
| Strike | 90.00 |
| Expiry date | 2025-01-17 |
| Day's range | 8.50 - 8.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
- Zacks
Novartis (NVS) Kisqali Positive for Early Breast Cancer
Novartis (NVS) Kisqali meets primary endpoint of invasive disease-free survival in certain patients with early breast cancer at risk of recurrence.
- Zacks
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up
Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.
- Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
© 2023 Yahoo. All rights reserved.
